

# THE USE OF DABIGATRAN ETEXILATE IN HOSPITALISED PATIENTS

Cuesta I, Delgado E, Gómez de Salazar E, Bermejo T.  
Pharmacy Department, Ramon y Cajal Hospital. Madrid, Spain

## BACKGROUND

Dabigatran etexilate (DE) is a new oral anticoagulant. It was included in the hospital's formulary as a restricted-use drug in December 2009.

## PURPOSE


To analyze DE use, compliance with the authorised indications and use restrictions, and to quantify the incidence of adverse events.

## METHODS

An observational, prospective, utilization study was carried out during four months in a general tertiary care hospital.


Pharmacy and Therapeutics Committee approved DE with prescription restricted to the Traumatology and Geriatrics Departments

Primary prevention of thromboembolic events in adults who have undergone elective total hip or knee replacement surgery



## RESULTS

138 patients started treatment with DE



• Overall, 57.24% of prescriptions stuck to the recommendations.

• Most commonly reported adverse events were: bleeding in surgical wound (7.97%) followed by gastrointestinal side effects (4.35%).  
• 15.94% of patients needed red blood cells concentrates transfusion

## CONCLUSION

Use of dabigatran etexilate was adequate in most patients, but more studies and a close pharmacosurveillance are needed to confirm the safety of this drug in common practice.